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ABSORPTION AND BIOAVAILABILITY OF
NEBULIZED MORPHINE
J. CHRUBASIK, H. WUST, G. FRIEDRICH AND E. GELLER
Recently it has been shown that postoperative
analgesia can be produced and maintained by the
inhalation of nebulized morphine [1]. However,
the use of this technique in a larger number of
patients revealed that pain relief was not always
satisfactory. The aim of this study therefore was to
evaluate the bioavailability of morphine adminis-
tered by inhalation.
METHODS AND RESULTS
Following institutional approval and informed
written consent, seven patients were studied (two
males, five females, mean age 49 (SD 19) yr, mean
weight 64 (SD13) kg) during abdominal surgery
with 66 % nitrous oxide and enflurane in oxygen,
plus neuromuscular blockade. All patients
suffered from rheumatic diseases requiring
chronic non-opioid analgesic treatment. During
operation, morphine 10 mg in sodium saline 5 ml
was injected into the reservoir of a standard
nebulizer (B + P Gmbh, 5206 Neunkirchen-
Seelscheid 2, FRG; particle size approx. 5 um
with an oxygen flow of 5 litre min"1) which was
placed between the tracheal tube and the semi-
closed anaesthetic breathing system with soda-
lime. Mean nebulization time was 42 (SEM 3.9)
min. The lungs were ventilated to achieve normo-
capnia with a tidal volume of 10 ml/kg body
weight and ventilatory rate of 12 b.p.m.
Pain in the early postoperative period was
treated with non-morphine analgesia in order to
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SUMMARY
During anaesthesia seven patients received a
bolus of morphine 10 mg injected into the nebuli-
zation reservoir placed between the tracheal tube
and the anaesthetic circle (IH). Five days after
operation the same seven patients received
morphine 10 mg i.m. On both occasions, venous
blood samples were taken before and every 15
min after administration over 4.5 h for measure-
ment of free morphine immunoreactivity by
radioimmunoassay. There was marked individual
variation in the serum morphine concentrations
produced following each route of administration.
The maximum serum morphine concentration
following inhaled morphine was approx. six
times lower than that after morphine i.m. and the
time of occurrence differed significantly
(P < 0.001). The individual relative bioavail-
abilities of inhaled morphine varied from 9% to
35%, with a mean of 17%.
allow almost complete elimination of the mor-
phine given by nebulization (IH). Upon com-
plaint of pain on the 5th day after operation,
morphine 10 mg was administered i.m. into the
gluteus maximus (IM). Venous blood samples
were taken before and every 15 min for 4.5 h after
the two morphine administrations for measure-
ment of free morphine immunoreactivity by
radioimmunoassay (Diagnostic Products Corpora-
tion, Los Angeles, cross reactivity to morphine-
3-glucuronide 0.22%).
Pharmacokinetic data were calculated for each
subject. Maximum serum concentration of mor-
phine (C11™) and the time of its occurrence (T"""1)
were obtained from the serum concentration-
time data. The individual elimination half-lives of
the terminal phase of the concentration-time
curves (7"^) were determined by linear regression
analysis when the terminal data points (at least
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FIG. 1. Mean serum morphine concentrations (SEM) after administration of (A) nebulized morphine
10 mg by inhalation and (B) morphine 10 mg i.m. in the same seven patients.
TABLE I. Pharmacokinetic details of seven patients who received nebulized morphine 10 mg by inhalation
(IH) and i.m. morphine 10 mg (IM) on two separate occasions. %CV = Coefficient of variation
Patient
No.
1
2
3
4
5
6
7
Mean
%cv
IH
IM
IH
IM
IH
IM
IH
IM
IH
IM
IH
IM
IH
IM
IH
IM
IH
IM
(ng ml"1)
9.0
70.2
15.0
86.5
21.4
56.9
9.8
101.3
12.1
60.4
7.2
60.9
8.3
58.3
11.8
70.6
42.0
24.1
'rm&x
(min)
44.4
28.7
56.8
21.7
37.3
54.6
44.0
20.4
55.8
20.1
39.1
25.2
40.1
25.2
45.5
28.0
17.4
43.4
(min)
144
143
104
134
180
80
123
49
142
105
86
150
288
79
152.4
105.7
44.0
36.1
AUC
(ng ml"1 min)
1009
10631
1544
10242
3031
8755
945
9787
1617
8198
899
10090
1320
7023
1480.7
9246.6
50.1
14.1
F(%)
9.5
15.1
34.6
9.7
19.7
8.9
18.8
16.6
54.8
three) plotted on a logarithmic axis declined
linearly. The area under the curves (AUC) was
calculated by the linear trapezoidal method and
was extrapolated to infinity by integrating the
terminal elimination phase. Individual relative
bioavailabilities of the inhaled morphine (F) were
calculated by dividing the area under the curve
after morphine inhalation (IH) by that after i.m.
(IM) administration for each subject.
For statistical analysis, the non-parametric
Wilcoxon matched pairs signed rank test was
used.
There was marked interindividual variation in
the serum morphine concentrations when mor-
phine was given by either inhalation or i.m.
injection. In most of the patients receiving
nebulized morphine the maximum serum con-
centration was reached within 45 min, when the
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mean peak concentration was 10.7 (SEM 1.6)
ng ml"1; the maximum serum concentration inde-
pendent of time was 11.8 (SEM 1.9) ng ml"1 (fig.
lA, table I). In contrast, following i.m. adminis-
tration of morphine a mean serum morphine
concentration of 63.5 (SEM 6.2) ng ml"1 was
reached within 15 min; the maximum serum con-
centration independent of time was 70.6 (SEM
6.4) (fig. 1B, table I). The maximum serum
morphine concentration (C1"*) after inhalation
was approximately six times lower than that after
i.m. administration and the times of their occur-
rence differed significantly (P < 0.001).
The relative bioavailability of morphine follow-
ing inhalation was approximately 9-35%, with a
mean of approximately 17%.
COMMENT
Gaensler and colleagues [2] observed that only
7-30 % of a nebulized drug inhaled into the lungs
was absorbed into the circulation, as at least 50 %
of the drug is lost on expiration. In addition, loss
of drug results from absorption onto equipment
and some morphine may be taken up by endo-
thelial cells [3]. Furthermore, patients may
swallow drug present in the pharynx.
Our results of the bioavailability of inhaled
nebulized morphine support previous observa-
tions in which a five-fold difference in serum
morphine concentration was found following the
inhalation and i.v. administration of morphine
given to achieve similar levels of postoperative
analgesia[l]. Plateau morphine concentrations of
approximately 4 ng ml"1 and 20 ng ml"1 were
achieved within 1 h after commencing inhalation
or i.v. treatment, respectively [1]. It is tempting to
speculate, therefore, that the mode of analgesia
after inhalation of morphine differs from that
achieved following other parenteral routes of
administration.
The low serum morphine concentrations ob-
served after inhalation of nebulized morphine
were found to be associated with fewer side-
effects than those seen after i.v. administration.
Moreover, it has been found recently that the
inhalation of morphine does not increase resting
airway resistance [4], which was thought previously
to be a severe side-effect of this method.
The great interindividual differences in systemic
absorption and the fact that lower serum con-
centrations of morphine occur after inhalation
than following oral [5] or rectal [6] administration
suggest that consistent pain relief cannot be
anticipated with nebulized morphine and that
repeated administration may result in potential
hazard.
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